Literature DB >> 33466831

Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease.

Milos Stanojlovic1, Jean Pierre Pallais2, Catherine M Kotz2,3.   

Abstract

Aside from the classical motor symptoms, Parkinson's disease also has various non-classical symptoms. Interestingly, orexin neurons, involved in the regulation of exploratory locomotion, spontaneous physical activity, and energy expenditure, are affected in Parkinson's. In this study, we hypothesized that Parkinson's-disease-associated pathology affects orexin neurons and therefore impairs functions they regulate. To test this, we used a transgenic animal model of Parkinson's, the A53T mouse. We measured body composition, exploratory locomotion, spontaneous physical activity, and energy expenditure. Further, we assessed alpha-synuclein accumulation, inflammation, and astrogliosis. Finally, we hypothesized that chemogenetic inhibition of orexin neurons would ameliorate observed impairments in the A53T mice. We showed that aging in A53T mice was accompanied by reductions in fat mass and increases in exploratory locomotion, spontaneous physical activity, and energy expenditure. We detected the presence of alpha-synuclein accumulations in orexin neurons, increased astrogliosis, and microglial activation. Moreover, loss of inhibitory pre-synaptic terminals and a reduced number of orexin cells were observed in A53T mice. As hypothesized, this chemogenetic intervention mitigated the behavioral disturbances induced by Parkinson's disease pathology. This study implicates the involvement of orexin in early Parkinson's-disease-associated impairment of hypothalamic-regulated physiological functions and highlights the importance of orexin neurons in Parkinson's disease symptomology.

Entities:  

Keywords:  Parkinson’s disease; neuromodulation; orexin

Mesh:

Substances:

Year:  2021        PMID: 33466831      PMCID: PMC7830608          DOI: 10.3390/ijms22020795

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  93 in total

Review 1.  Neurodegeneration and inflammation in Parkinson's disease.

Authors:  Sudarshan Phani; John D Loike; Serge Przedborski
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

Review 2.  Orexins, feeding, and energy balance.

Authors:  Elodie M Girault; Chun-Xia Yi; Eric Fliers; Andries Kalsbeek
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 3.  A review of the role of orexin system in pain modulation.

Authors:  Bibi Marjan Razavi; Hossein Hosseinzadeh
Journal:  Biomed Pharmacother       Date:  2017-03-27       Impact factor: 6.529

4.  Astrocytic expression of Parkinson's disease-related A53T alpha-synuclein causes neurodegeneration in mice.

Authors:  Xing-Long Gu; Cai-Xia Long; Lixin Sun; Chengsong Xie; Xian Lin; Huaibin Cai
Journal:  Mol Brain       Date:  2010-04-21       Impact factor: 4.041

5.  Huntingtin is required for normal excitatory synapse development in cortical and striatal circuits.

Authors:  Spencer U McKinstry; Yonca B Karadeniz; Atesh K Worthington; Volodya Y Hayrapetyan; M Ilcim Ozlu; Karol Serafin-Molina; W Christopher Risher; Tuna Ustunkaya; Ioannis Dragatsis; Scott Zeitlin; Henry H Yin; Cagla Eroglu
Journal:  J Neurosci       Date:  2014-07-09       Impact factor: 6.167

Review 6.  Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.

Authors:  Lisa Fellner; Kurt A Jellinger; Gregor K Wenning; Nadia Stefanova
Journal:  Acta Neuropathol       Date:  2011-05-12       Impact factor: 17.088

7.  The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder.

Authors:  Anna Heintz-Buschart; Urvashi Pandey; Tamara Wicke; Friederike Sixel-Döring; Annette Janzen; Elisabeth Sittig-Wiegand; Claudia Trenkwalder; Wolfgang H Oertel; Brit Mollenhauer; Paul Wilmes
Journal:  Mov Disord       Date:  2017-08-26       Impact factor: 10.338

Review 8.  Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease.

Authors:  Yaping Shao; Weidong Le
Journal:  Mol Neurodegener       Date:  2019-01-11       Impact factor: 14.195

9.  Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Catherine M Kotz
Journal:  Front Neurosci       Date:  2019-07-30       Impact factor: 4.677

10.  Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis.

Authors:  Janusz W Błaszczyk
Journal:  Front Neurosci       Date:  2016-06-09       Impact factor: 4.677

View more
  3 in total

Review 1.  Potential Crosstalk Between Parkinson's Disease and Energy Metabolism.

Authors:  Meiqiu Liu; Qian Jiao; Xixun Du; Mingxia Bi; Xi Chen; Hong Jiang
Journal:  Aging Dis       Date:  2021-12-01       Impact factor: 6.745

Review 2.  Physiological Role of Orexinergic System for Health.

Authors:  Ines Villano; Marco La Marra; Girolamo Di Maio; Vincenzo Monda; Sergio Chieffi; Ezia Guatteo; Giovanni Messina; Fiorenzo Moscatelli; Marcellino Monda; Antonietta Messina
Journal:  Int J Environ Res Public Health       Date:  2022-07-08       Impact factor: 4.614

Review 3.  Orexin, serotonin, and energy balance.

Authors:  Vijayakumar Mavanji; Brianna Pomonis; Catherine M Kotz
Journal:  WIREs Mech Dis       Date:  2021-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.